Zoetis Inc. to Post Q4 2024 Earnings of $1.48 Per Share, Zacks Research Forecasts (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Research analysts at Zacks Research cut their Q4 2024 earnings per share (EPS) estimates for Zoetis in a report released on Monday, April 29th. Zacks Research analyst E. Bagri now expects that the company will post earnings of $1.48 per share for the quarter, down from their prior estimate of $1.50. The consensus estimate for Zoetis’ current full-year earnings is $5.79 per share. Zacks Research also issued estimates for Zoetis’ Q1 2025 earnings at $1.49 EPS, Q2 2025 earnings at $1.65 EPS, FY2025 earnings at $6.38 EPS, Q1 2026 earnings at $1.66 EPS and FY2026 earnings at $6.94 EPS.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the firm earned $1.15 earnings per share. Zoetis’s quarterly revenue was up 8.5% on a year-over-year basis.

Several other research analysts also recently issued reports on ZTS. Barclays cut their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. The Goldman Sachs Group upped their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $218.00.

Zoetis Stock Up 0.9 %

Shares of NYSE ZTS opened at $159.78 on Tuesday. The firm’s 50-day moving average is $171.21 and its two-hundred day moving average is $179.23. The company has a market capitalization of $73.08 billion, a PE ratio of 31.51, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. Zoetis has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.08%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 over the last quarter. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Zoetis

Hedge funds and other institutional investors have recently modified their holdings of the company. Blue Bell Private Wealth Management LLC raised its holdings in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the period. Independence Bank of Kentucky raised its stake in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares during the period. Private Wealth Management Group LLC purchased a new position in shares of Zoetis in the 4th quarter valued at $33,000. Webster Bank N. A. lifted its holdings in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares in the last quarter. Finally, Ramirez Asset Management Inc. purchased a new stake in Zoetis during the 3rd quarter worth $35,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.